Explore

Weill Cornell Medicine Showcases AI-Powered Devices for Healthcare Innovation

Weill Cornell Medicine Showcases AI-Powered Devices for Healthcare Innovation

Weill Cornell Medicine is hosting an event titled 'Revolutionizing Healthcare with AI-Powered Devices' as part of #AIWeekNY, a community-led festival celebrating innovation in the AI ecosystem. The event will showcase various digital health innovations and technologies. Featured technologies include EmulatRx, an AI platform designed to support clinical trial design using real-world patient data, presented by Weishen Pan, PhD. Bobak Mosadegh, PhD, will present WAV AI, an AI-based tool for detecting fistula stenosis by analyzing sounds. Yiye Zhang, PhD, MS, will introduce an Epic-integrated clinical decision support tool for predicting postpartum depression risk using electronic health record data. Additionally, Rayaz A. Malik, MBChB, PhD, FRCP, will present on corneal confocal microscopy, a noninvasive approach for detecting neurodegenerative diseases through changes in corneal nerve fibers, utilizing quantitative imaging and predictive analysis.

AI-Powered Diagnostics Enhance Early Disease Detection Across Medical Fields

AI-Powered Diagnostics Enhance Early Disease Detection Across Medical Fields

AI-powered diagnostics are significantly improving early disease detection across various medical disciplines, including imaging, pathology, and biomarkers. Machine learning models are now being integrated into clinical workflows to analyze medical data, such as imaging scans, pathology slides, and multiomic data. These AI systems are capable of identifying subtle patterns that are often imperceptible to the human eye, leading to earlier identification of conditions like cancer, cardiovascular disease, and neurodegenerative disorders. Key breakthroughs include deep learning systems accurately flagging suspicious lesions in CT, MRI, and mammography scans, digital pathology platforms quantifying tumor features and predicting prognosis from whole slide images, and molecular models integrating genomic and proteomic signals to identify early-stage disease biomarker signatures. Several AI tools have progressed through regulatory review and are currently undergoing evaluation in multicenter trials, moving towards...

HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

The U.S. Department of Health and Human Services (HHS) has announced a new program and three complementary projects aimed at significantly speeding up clinical trials through the integration of artificial intelligence (AI), advanced computational models, and real-time analysis. The core initiative, named SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials), seeks to develop AI-powered platforms that will continuously and adaptively support clinical trial designs. This program includes the creation of a phaseless design engine to simulate trials for faster results with fewer patients, a continuous inference engine for real-time data analysis and trial adaptations, and an agentic AI operations layer to automate startup activities and data collection. These efforts are part of a broader strategy by HHS to transform U.S. clinical trials, building on previous initiatives like Operation TrialBlazer and the FDA's pilot program using AI for real-time clinical trial data monitoring. The goal ...

CSL Licenses Anti-Claudin-1 Antibody from Alentis Therapeutics in $1.55 Billion Deal for Kidney and Liver Diseases

CSL Licenses Anti-Claudin-1 Antibody from Alentis Therapeutics in $1.55 Billion Deal for Kidney and Liver Diseases

CSL Licenses Anti-Claudin-1 Antibody from Alentis Therapeutics in $1.55 Billion Deal for Kidney and Liver Diseases

Regeneron Expands Global Immunology Alliance with Sanofi, Securing $1 Billion Upfront

Regeneron Expands Global Immunology Alliance with Sanofi, Securing $1 Billion Upfront

Regeneron Expands Global Immunology Alliance with Sanofi, Securing $1 Billion Upfront

ProMIS Neurosciences Appoints Ivana Rubino as Chief Commercial Officer Amidst Ongoing Alzheimer's Drug Trial

ProMIS Neurosciences Appoints Ivana Rubino as Chief Commercial Officer Amidst Ongoing Alzheimer's Drug Trial

ProMIS Neurosciences Appoints Ivana Rubino as Chief Commercial Officer Amidst Ongoing Alzheimer's Drug Trial

Alzheimer's Treatment Centers of America Seeks Advisory Board Members to Advance Personalized Care

Alzheimer's Treatment Centers of America Seeks Advisory Board Members to Advance Personalized Care

Alzheimer's Treatment Centers of America (ATCA) is actively recruiting accomplished healthcare executives, technology leaders, founders, entrepreneurs, operators, investors, and business leaders to join its Advisory Board. This initiative aims to guide the company's next phase of growth, focusing on the future of personalized Alzheimer's care. ATCA was established to challenge the conventional approach to cognitive decline, which often involves simply diagnosing, managing, and accepting the condition. The organization integrates Artificial Intelligence (AI) with personalized precision medicine to identify and address over 100 potential root causes of cognitive decline. This approach utilizes patient-specific clinical data to inform individualized treatment strategies. An observational study of ATCA's AI protocol showed that 80% of participants with mild cognitive impairment experienced no further decline, though this finding does not establish causation or guarantee similar future results. ATCA is committe...

Japan Aims to Boost Pharmaceutical Industry Growth to G7 Average, Focuses on AI-Enabled Drug Discovery

Japan Aims to Boost Pharmaceutical Industry Growth to G7 Average, Focuses on AI-Enabled Drug Discovery

Japan Aims to Boost Pharmaceutical Industry Growth to G7 Average, Focuses on AI-Enabled Drug Discovery

Utah Expands AI Sandbox for Healthcare, Approving AI-Powered Prescriptions and Women's Health Pilots

Utah Expands AI Sandbox for Healthcare, Approving AI-Powered Prescriptions and Women's Health Pilots

Utah regulators have announced a significant expansion of their 'AI sandbox' program, which allows the state's Office of Artificial Intelligence Policy (OAIP) to waive regulations for companies testing AI products under state supervision. As part of this expansion, a startup named Nolla Health will launch an AI-powered service in Utah. This service will assess patients for mild-to-moderate acne treatment using structured intake questionnaires and by analyzing skin photos. The AI will then determine if a low-risk drug from a pre-approved list is appropriate. Initially, a licensed clinician will review and sign off on all AI-generated prescriptions, but Nolla Health may eventually be permitted to prescribe drugs without prior human review. This initiative is part of a broader effort by Utah to foster innovation in AI within the healthcare sector, including additional pilots for women's health.

Vaxcyte's VAX-31 Pneumococcal Vaccine Shows Superiority in Phase 3 Trial Against Pfizer and Merck Competitors

Vaxcyte's VAX-31 Pneumococcal Vaccine Shows Superiority in Phase 3 Trial Against Pfizer and Merck Competitors

Vaxcyte's VAX-31 Pneumococcal Vaccine Shows Superiority in Phase 3 Trial Against Pfizer and Merck Competitors

Blood-Based Biomarkers Revolutionize Alzheimer's Disease Detection and Therapeutic Development

Blood-Based Biomarkers Revolutionize Alzheimer's Disease Detection and Therapeutic Development

Blood-based biomarkers are significantly advancing the detection, monitoring, and therapeutic development for Alzheimer's disease (AD). Frontage Laboratories offers a comprehensive suite of validated neuro biomarker assays to support AD research and drug development. These assays are compatible with advanced platforms such as Quanterix Simoa HD-X, Fujirebio Lumipulse G1200, and Alamar Biosciences, Inc. ARGO HT NULISA, with validated methods for plasma, serum, and cerebrospinal fluid (CSF). Established reference biomarkers for AD pathology, including Amyloid PET and CSF p-tau181/Aβ42, demonstrate high sensitivity and specificity, ranging from 85% to 95%. Additionally, peripherin is emerging as a promising diagnostic and prognostic biomarker for neurodegenerative diseases. This development is crucial given that AD is a complex and progressive neurodegenerative disorder affecting over 55 million people globally, making early and accurate diagnosis critical for effective intervention and management.

Johnson Johnson Seeks AI Manager to Enhance Patient Engagement and Experience

Johnson Johnson Seeks AI Manager to Enhance Patient Engagement and Experience

Johnson Johnson Seeks AI Manager to Enhance Patient Engagement and Experience